Raviraj Karia is a chartered accountant and senior finance leader with more than 23 years of experience across pharmaceuticals, healthcare, clinical research, logistics, and private equity. His career reflects deep expertise in corporate governance, strategic finance, and business partnering, having worked closely with Boards, Promoters, CEOs, and global leadership teams.

Across leadership roles at Intas Pharmaceuticals, Sakar Healthcare, Lambda Therapeutics, Shalby Hospitals, Gati, GVFL, and Claris Lifesciences, he has delivered significant impact—managing multi billion dollar financing programs, leading India’s largest outbound pharma acquisition, facilitating marquee private equity investments, and executing global audits across Europe, the US, Latin America, and emerging markets.

Concord Biotech is a R&D driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It has a presence in more than 70 countries worldwide.

The company’s consolidated net profit declined 33.6% to Rs 63.58 crore on 20.3% increase in net sales to Rs 247.06 crore in Q2 FY26 over Q2 FY25.

The scrip rose 0.20% to Rs 1335 on the BSE.